ArticleESC heart failure2020

Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial.

Rolf Wachter et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.